Breast Cancer-Related Lymphedema (BCRL) and Bioimpedance Spectroscopy: Long-Term Follow-Up, Surveillance Recommendations, and Multidisciplinary Risk Factors.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
20
04
2023
accepted:
06
07
2023
medline:
12
9
2023
pubmed:
3
8
2023
entrez:
3
8
2023
Statut:
ppublish
Résumé
Early detection and intervention for breast cancer-related lymphedema (BCRL) significantly decreases progression to persistent BCRL (pBCRL). We aimed to provide long-term follow-up on our early detection with bioimpedance spectroscopy (BIS) and early home intervention demonstrating reduced pBCRL to guide surveillance recommendations. In total, 148 female patients with breast cancer who had axillary lymph node dissection (ALND) from November 2014 to December 2017 were analyzed. Baseline BIS measurements and postoperative follow-up occurred every 3 months for 1 year, biannual for 1 year, and then annually. An elevated BIS triggered evaluation and initiation of at-home interventions with reassessment for resolution versus persistent BCRL (pBCRL). High-risk factors and timing were analyzed. Mean follow-up was 55 months, and 65 (44%) patients had an abnormal BIS. Of these, 54 (82%) resolved with home intervention. The overall pBCRL rate was 8%. Average time to first abnormal BIS was 11.7 months. None of the stage 0 patients (0/34) and only 5/25 (20%) of stage 1 patients had pBCRL. All of stage 2 and stage 3 patients (7/7) had pBCRL. pBCRL correlated with number of positive nodes, percentage of positive nodes, stage of lymphedema at diagnosis, and recurring abnormal BIS measurements (p < 0.05). We have shown that patients undergoing ALND with early BCRL identified by BIS who performed home interventions had an 8% pBCRL rate. Patients at high risk for pBCRL should have routine surveillance starting at 9 months postoperatively to identify an opportunity for early intervention.
Sections du résumé
BACKGROUND
BACKGROUND
Early detection and intervention for breast cancer-related lymphedema (BCRL) significantly decreases progression to persistent BCRL (pBCRL). We aimed to provide long-term follow-up on our early detection with bioimpedance spectroscopy (BIS) and early home intervention demonstrating reduced pBCRL to guide surveillance recommendations.
PATIENTS AND METHODS
METHODS
In total, 148 female patients with breast cancer who had axillary lymph node dissection (ALND) from November 2014 to December 2017 were analyzed. Baseline BIS measurements and postoperative follow-up occurred every 3 months for 1 year, biannual for 1 year, and then annually. An elevated BIS triggered evaluation and initiation of at-home interventions with reassessment for resolution versus persistent BCRL (pBCRL). High-risk factors and timing were analyzed.
RESULTS
RESULTS
Mean follow-up was 55 months, and 65 (44%) patients had an abnormal BIS. Of these, 54 (82%) resolved with home intervention. The overall pBCRL rate was 8%. Average time to first abnormal BIS was 11.7 months. None of the stage 0 patients (0/34) and only 5/25 (20%) of stage 1 patients had pBCRL. All of stage 2 and stage 3 patients (7/7) had pBCRL. pBCRL correlated with number of positive nodes, percentage of positive nodes, stage of lymphedema at diagnosis, and recurring abnormal BIS measurements (p < 0.05).
CONCLUSIONS
CONCLUSIONS
We have shown that patients undergoing ALND with early BCRL identified by BIS who performed home interventions had an 8% pBCRL rate. Patients at high risk for pBCRL should have routine surveillance starting at 9 months postoperatively to identify an opportunity for early intervention.
Identifiants
pubmed: 37535267
doi: 10.1245/s10434-023-13956-9
pii: 10.1245/s10434-023-13956-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6258-6265Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023. Society of Surgical Oncology.
Références
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708 .
doi: 10.3322/caac.21708
pubmed: 35020204
Zhang X, Oliveri JM, Paskett ED. Features, Predictors, and treatment of breast cancer-related lymphedema. Curr Breast Cancer Rep. 2020;12(4):244–54. https://doi.org/10.1007/s12609-020-00381-0 .
doi: 10.1007/s12609-020-00381-0
pubmed: 34012502
pmcid: 8130904
McLaughlin SA, Staley AC, Vicini F, et al. Considerations for clinicians in the diagnosis, prevention, and treatment of breast cancer-related lymphedema: recommendations from a multidisciplinary expert ASBrS panel. Ann Surg Oncol. 2017;24(10):2818–26. https://doi.org/10.1245/s10434-017-5982-4 .
doi: 10.1245/s10434-017-5982-4
pubmed: 28766232
Gärtner R, Jensen MB, Kronborg L, Ewertz M, Kehlet H, Kroman N. Self-reported arm-lymphedema and functional impairment after breast cancer treatment–a nationwide study of prevalence and associated factors. Breast Edinb Scotl. 2010;19(6):506–15. https://doi.org/10.1016/j.breast.2010.05.015 .
doi: 10.1016/j.breast.2010.05.015
Lawenda BD, Mondry TE, Johnstone PAS. Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin. 2009;59(1):8–24. https://doi.org/10.3322/caac.20001 .
doi: 10.3322/caac.20001
pubmed: 19147865
De Vrieze T, Gebruers N, Nevelsteen I, et al. Breast cancer-related lymphedema and its treatment: how big is the financial impact? Support Care Cancer. 2021;29(7):3801–13. https://doi.org/10.1007/s00520-020-05890-3 .
doi: 10.1007/s00520-020-05890-3
pubmed: 33236211
Document C. The diagnosis and treatment of peripheral lymphedema: 2020 consensus document of the international society of lymphology. Lymphology. 2020;53(1):1–2. https://doi.org/10.2458/lymph.4649 .
doi: 10.2458/lymph.4649
Rockson SG. Lymphedema after breast cancer treatment. N Engl J Med. 2018;379(20):1937–44. https://doi.org/10.1056/NEJMcp1803290 .
doi: 10.1056/NEJMcp1803290
pubmed: 30428297
Shah C, Vicini FA, Arthur D. Bioimpedance spectroscopy for breast cancer related lymphedema assessment: clinical practice guidelines. Breast J. 2016;22(6):645–50. https://doi.org/10.1111/tbj.12647 .
doi: 10.1111/tbj.12647
pubmed: 27487985
Shah C, Zambelli-Weiner A, Delgado N, Sier A, Bauserman R, Nelms J. The impact of monitoring techniques on progression to chronic breast cancer-related lymphedema: a meta-analysis comparing bioimpedance spectroscopy versus circumferential measurements. Breast Cancer Res Treat. 2021;185(3):709–40. https://doi.org/10.1007/s10549-020-05988-6 .
doi: 10.1007/s10549-020-05988-6
pubmed: 33245458
Kaufman DI, Shah C, Vicini FA, Rizzi M. Utilization of bioimpedance spectroscopy in the prevention of chronic breast cancer-related lymphedema. Breast Cancer Res Treat. 2017;166(3):809–15. https://doi.org/10.1007/s10549-017-4451-x .
doi: 10.1007/s10549-017-4451-x
pubmed: 28831632
pmcid: 5680358
Whitworth PW, Cooper A. Reducing chronic breast cancer-related lymphedema utilizing a program of prospective surveillance with bioimpedance spectroscopy. Breast J. 2018;24(1):62–5. https://doi.org/10.1111/tbj.12939 .
doi: 10.1111/tbj.12939
pubmed: 29063664
Yang EJ, Ahn S, Kim EK, et al. Use of a prospective surveillance model to prevent breast cancer treatment-related lymphedema: a single-center experience. Breast Cancer Res Treat. 2016;160(2):269–76. https://doi.org/10.1007/s10549-016-3993-7 .
doi: 10.1007/s10549-016-3993-7
pubmed: 27665585
pmcid: 5065580
Gillespie TC, Sayegh HE, Brunelle CL, Daniell KM, Taghian AG. Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments. Gland Surg. 2018;7(4):379–403. https://doi.org/10.21037/gs.2017.11.04 .
doi: 10.21037/gs.2017.11.04
pubmed: 30175055
pmcid: 6107585
Swaroop MN, Ferguson CM, Horick NK, et al. Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort. Breast Cancer Res Treat. 2015;151(2):393–403. https://doi.org/10.1007/s10549-015-3408-1 .
doi: 10.1007/s10549-015-3408-1
pubmed: 25940996
pmcid: 4432026
Koelmeyer LA, Gaitatzis K, Dietrich MS, et al. Risk factors for breast cancer-related lymphedema in patients undergoing 3 years of prospective surveillance with intervention. Cancer. 2022;128(18):3408–15. https://doi.org/10.1002/cncr.34377 .
doi: 10.1002/cncr.34377
pubmed: 35797441
Kim JS, Kim JH, Chang JH, Kim DW, Shin KH. Prediction of breast cancer-related lymphedema risk after postoperative radiotherapy via multivariable logistic regression analysis. Front Oncol. 2022;12:1026043. https://doi.org/10.3389/fonc.2022.1026043 .
doi: 10.3389/fonc.2022.1026043
pubmed: 36387231
pmcid: 9643832
Kassamani YW, Brunelle CL, Gillespie TC, et al. Diagnostic criteria for breast cancer-related lymphedema of the upper extremity: the need for universal agreement. Ann Surg Oncol. 2022;29(2):989–1002. https://doi.org/10.1245/s10434-021-10645-3 .
doi: 10.1245/s10434-021-10645-3
pubmed: 34505218
Ridner SH, Dietrich MS, Boyages J, et al. A comparison of bioimpedance spectroscopy or tape measure triggered compression intervention in chronic breast cancer lymphedema prevention. Lymphat Res Biol. 2022;20(6):618–28. https://doi.org/10.1089/lrb.2021.0084 .
doi: 10.1089/lrb.2021.0084
pubmed: 35099283
pmcid: 9810346
Koelmeyer LA, Borotkanics RJ, Alcorso J, et al. Early surveillance is associated with less incidence and severity of breast cancer-related lymphedema compared with a traditional referral model of care. Cancer. 2019;125(6):854–62. https://doi.org/10.1002/cncr.31873 .
doi: 10.1002/cncr.31873
pubmed: 30521080
Cornish BH, Chapman M, Hirst C, et al. Early diagnosis of lymphedema using multiple frequency bioimpedance. Lymphology. 2001;34(1):2–11.
pubmed: 11307661
Ridner SH, Dietrich MS, Cowher MS, et al. A randomized trial evaluating bioimpedance spectroscopy versus tape measurement for the prevention of lymphedema following treatment for breast cancer: interim analysis. Ann Surg Oncol. 2019;26(10):3250–9. https://doi.org/10.1245/s10434-019-07344-5 .
doi: 10.1245/s10434-019-07344-5
pubmed: 31054038
pmcid: 6733825
Soran A, Ozmen T, McGuire KP, et al. The importance of detection of subclinical lymphedema for the prevention of breast cancer-related clinical lymphedema after axillary lymph node dissection; a prospective observational study. Lymphat Res Biol. 2014;12(4):289–94. https://doi.org/10.1089/lrb.2014.0035 .
doi: 10.1089/lrb.2014.0035
pubmed: 25495384
Whitworth P, Vicini F, Valente SA, et al. Reducing rates of chronic breast cancer–related lymphedema with screening and early intervention: an update of recent data. J Cancer Surviv. 2022. https://doi.org/10.1007/s11764-022-01242-8 .
doi: 10.1007/s11764-022-01242-8
pubmed: 35947288
Havens LM, Brunelle CL, Gillespie TC, et al. Use of technology to facilitate a prospective surveillance program for breast cancer-related lymphedema at the Massachusetts General Hospital. mHealth. 2021;7:11. https://doi.org/10.21037/mhealth-19-218 .
doi: 10.21037/mhealth-19-218
pubmed: 33634194
pmcid: 7882272
Bucci LK, Brunelle CL, Bernstein MC, et al. Subclinical lymphedema after treatment for breast cancer: risk of progression and considerations for early intervention. Ann Surg Oncol. 2021;28(13):8624–33. https://doi.org/10.1245/s10434-021-10173-0 .
doi: 10.1245/s10434-021-10173-0
pubmed: 34117574
Liu F, Li F, Fu MR, et al. Self-management strategies for risk reduction of subclinical and mild stage of breast cancer–related lymphedema: a longitudinal, quasi-experimental study. Cancer Nurs. 2021;44(6):E493. https://doi.org/10.1097/NCC.0000000000000919 .
doi: 10.1097/NCC.0000000000000919
pubmed: 34694088
Kilgore LJ, Korentager SS, Hangge AN, et al. Reducing breast cancer-related lymphedema (BCRL) through prospective surveillance monitoring using bioimpedance spectroscopy (BIS) and patient directed self-interventions. Ann Surg Oncol. 2018;25(10):2948–52. https://doi.org/10.1245/s10434-018-6601-8 .
doi: 10.1245/s10434-018-6601-8
pubmed: 29987599
Fu MR, Axelrod D, Guth AA, et al. Proactive approach to lymphedema risk reduction: a prospective study. Ann Surg Oncol. 2014;21(11):3481–9. https://doi.org/10.1245/s10434-014-3761-z .
doi: 10.1245/s10434-014-3761-z
pubmed: 24809302
pmcid: 4163073
Ashikaga T, Krag DN, Land SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102(2):111–8. https://doi.org/10.1002/jso.21535 .
doi: 10.1002/jso.21535
pubmed: 20648579
pmcid: 3072246
Wernicke AG, Goodman RL, Turner BC, et al. A 10-year follow-up of treatment outcomes in patients with early stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearance. Breast Cancer Res Treat. 2011;125(3):893–902. https://doi.org/10.1007/s10549-010-1167-6 .
doi: 10.1007/s10549-010-1167-6
pubmed: 20853176
Montagna G, Zhang J, Sevilimedu V, et al. Risk factors and racial and ethnic disparities in patients with breast cancer–related lymphedema. JAMA Oncol. 2022;8(8):1195–200. https://doi.org/10.1001/jamaoncol.2022.1628 .
doi: 10.1001/jamaoncol.2022.1628
pubmed: 35679026
pmcid: 9185510